Wake Forest University Health Sciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).
Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.
Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.
Top-decile sponsor footprint
Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,140 total, page 16 of 23
Reducing Lung Cancer-Related Anxiety (RELAX)
NCT02063828
Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells
NCT02425800
A Trial of RSL Versus WL for Malignant Breast Disease
NCT02522468
Impact of Skin to Skin Contact on Maternal Satisfaction, Pain Scores, and Narcotic Usage After Cesarean Delivery
NCT02533167
Perineural Steroids for Peripheral Nerve Blocks
NCT02462148
MICU Recovery Clinic
NCT02560129
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease
NCT03130036
Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02337478
Do Peanut Shaped Birthing Balls Reduce the Length of Labor in Patients With Epidural Analgesia?
NCT02539563
Strength Testing After Nitrate Delivery (STAND) in ICU Patients
NCT02293616
Systemic Steroids for Peripheral Nerve Blocks
NCT02464176
Motor Development of Children That Have Surgery as Newborns for Complex Congenital Heart Disease
NCT02781545
Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3
NCT02426658
Improving Resection Rates Among African Americans With NSCLC
NCT01885455
Operative and Non-operative Treatment of Traumatic Arthrotomies
NCT02841644
Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart
NCT02462161
Website Application Based Education and Text Messaging in Improving Skin Wound Care in Patients Undergoing Mohs Surgery
NCT02373722
Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery
NCT02356471
Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases
NCT02248597
HIRREM in Military Personnel
NCT03230890
Nutrition Education for Cardiovascular Disease Prevention in Spinal Cord Injury
NCT02368405
Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease
NCT02984540
Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy
NCT02375334
Cilostazol After Lower Extremity Arterial Revascularization Trial
NCT02374957
CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
NCT02232152
Goal-directed Fluid Therapy on Complications After Pancreaticoduodenectomy
NCT03699917
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
NCT02343549
Study of the Immune Response After Vaccination in Multiple Myeloma Patients
NCT02294487
Qsymia as an Adjunct to Surgical Therapy in the Superobese
NCT02301416
Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies
NCT02305979
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
NCT02166255
LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
NCT02328105
Intravesicular Onabotulinumtoxin A in Interstitial Cystitis
NCT02297100
Spironolactone After Liver Transplant
NCT02883400
Cutaneous Lupus Medication Experience Study
NCT02176148
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT02168907
Project 1, Study 2: The Combined Impact of Nicotine Replacement and Spectrum Cigarettes
NCT02301325
Botulinum Toxin for the Management of Chronic Orchialgia
NCT02058836
Glioma Modified Atkins-based Diet in Patients With Glioblastoma
NCT02286167
Arthritis Pilot for Preserving Muscle While Losing Weight
NCT02239939
A Pilot Study to Examine the Effects of Vitamin D Supplementation on Mitochondrial Bioenergetics in Older Adults
NCT02445066
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
NCT02265198
A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients
NCT02196038
Project 2: Strategies for Reducing Nicotine Content in Cigarettes
NCT02139930
Attention Deficit/Hyperactivity Disorder Internet Survey Study in a College Student Population
NCT02251080
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
NCT02168140
Be a Champion! Comprehensive School Physical Activity Program
NCT02465372
Evaluation of Minimally Invasive Subcortical Parafascicular Access for Clot Evacuation
NCT02331719
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)
NCT03317925
Communication Effectiveness in Cancer Treatment
NCT02197091
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 96 |
| Phase 2 | 143 |
| Phase 3 | 31 |
| Phase 4 | 80 |
Therapeutic Areas
What is open in the Wake Forest University Health Sciences pipeline
174 recruiting of 1,140 indexed (15% open); 724 completed (64%).
Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Wake Forest University Health Sciences: open-pipeline peers nationwide
Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,140 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
- University of Florida · 1,106 trials · 15% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Baylor University · 15% recruiting · 33 trials
- Cornell University · 15% recruiting · 66 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
Related
What to do with this Wake Forest University Health Sciences page
1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.
- 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.